NEWS Redx Pharma and Dishman in process technology collaboration Events
9-11 October 2012 CPhI Worldwide Madrid, Spain
www.cphi.com
9-11 October 2012 ICSE Europe Madrid, Spain
www.icsexpo.com
9-11 October 2012 Innopack
Madrid, Spain
www.innopack-pharma.com
9-11 October 2012 P-M
MEC Europe Madrid, Spain
www.cphi.com
6-8 November 2012 PEGS Europe Vienna, Austria
www.pegsummiteurope.com
12-14 November 2012 BIO-E
Europe
Hamburg, Germany
www.ebdgroup.com/bioeurope
19-20 November 2012 New Horizons in Catalysis Prague, Czech Republic
www.scientificupdate.co.uk
19-20 November 2012 Polymorphism & Crystallisation Prague, Czech Republic
www.scientificupdate.co.uk
27-28 November 2012 The AgroChemical Conference 2012
Newmarket (nr Cambridge), UK
www.avakado.eu
19-20 March 2013 The Peptide Conference 2013 Newmarket (nr Cambridge), UK
www.avakado.eu
19-20 March 2013 Dynamic Outsourcing for Life Sciences
Newmarket (nr Cambridge), UK
www.avakado.eu
Early-stage drug development company Redx Pharma has established a licensing agreement that will allow Dishman Pharmaceuticals & Chemicals to use process technology patented by Redx. Under the agreement, Dishman, a global supplier to the pharmaceutical industry, will employ the technology for the synthesis of statins, a high-
selling class of prescription drugs. Financial terms were not disclosed but it is expected that the collaboration will generate multi-million-dollar revenues for both companies.
Redx Pharma is developing a portfolio of new drug candidates across multiple therapeutic areas and its development programmes represent licensing opportunities for large pharma companies.
Earlier this year the company launched its first spin-out business, Redx Oncology, and is currently planning a second spin-out, Redx Anti-Infectives. Dishman has a portfolio of products and development, scale-up and manufacturing services it provides to the pharmaceutical industry on a global basis.
New investments and ownership structure at SARomics Biostructures
Innovationsbron AB and Lund University Innovation System AB (LUIS AB) are to invest in and become new co-owners of structural biology service provider SARomics Biostructures AB alongside the company’s founders. The company said the new investment would allow it to expand its primary business of generating 3D structural information of proteins and protein-ligand complexes. SARomics Biostructures is a major user of MAX-lab, the Swedish national synchrotron facility located in Lund, and aims to position itself as a leading European structural biology service provider when the new MAX IV synchrotron opens in 2015.
SARomics Biostructures’ gene- to-structure platform has been applied to determine the structures of a large number of drug targets, biopharmaceuticals, and industrial enzymes for partners from both the life science industry and academia worldwide. The company is currently expanding its off-the- shelf portfolio of ‘ready-made’ crystal structures of drug targets and will also engage in internal lead discovery programmes. The company’s structure-based drug design support includes protein crystallisation, X-ray protein structure determination, computational chemistry, protein modeling and NMR spectroscopy analyses. It is equipped with state-of-the-art robotics for
MiReven receives A$500,000 funding from MRCF
MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti- cancer potential of miR-7, has received a further A$500,000 investment from the Medical Research Commercialisation Fund (MRCF) due to the successful completion of various technical and commercial milestones. This brings the total amount the MRCF has invested in MiReven since its foundation in 2010 to A$1 million.
MiReven recently signed two international R&D collaborations to investigate the therapeutic efficacy of systemically delivered
12 sp2 Inter-Active September/October 2012
miR-7 in several different cancer models.
The first agreement is with Silence Therapeutics, and will use Silence’s proprietary AtuPLEX and DACC delivery systems to evaluate miR-7 in various cancer models. Silence will formulate a miR-7 mimetic and then use it to undertake in-vitro and in-vivo studies. Once these studies are complete, MiReven will identify a development partner to take miR- 7 into the clinic.
A second agreement, this time with an undisclosed international company, takes a similarly strategic approach to positioning miR-7 as a cancer therapeutic.
low-volume high-throughput crystallisation and X-ray diffraction experiments. Founded in 1994, Innovationsbron develops and invests in companies with international growth potential. Its investment in SARomics Biostructures is part of a co- investment project with the European Regional Development Fund (ERDF). LUIS AB supports and finances the
commercialisation process for new ideas emanating from research results at Lund University. In addition it enables the University to form new research-based companies and it also assists inventors in forming licensing deals. LUIS AB currently holds equity in 38 spin-out companies.
CLC bio acquires Molegro
CLC bio has acquired Molegro, a specialised software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound activities against a receptor, and determination of molecule similarity. The acquisition supports CLC bio’s strategy of expanding its bioinformatics offerings beyond next generation sequencing. CLC bio will invest into the continued development of the acquired protein-ligand docking and data modeling software. All existing Molegro customers with an active support and software upgrade contract have been transferred to CLC bio.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44